Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2018

Summary:

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Melanin-concentrating hormone receptor 1 also known as MCH1 is one of the human melanin-concentrating hormone receptors. MCH1 is a target for the orexigenic peptide leptin, which supports a role for MCH receptors in the control of food intake and energy expenditure. MCH1 helps in regulation of stress, anxiety and depression.

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) pipeline Target constitutes close to 5 molecules. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Metabolic Disorders and Gastrointestinal which include indications Obesity and Non-Alcoholic Steatohepatitis (NASH).

The latest report Melanin Concentrating Hormone Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The report provides a snapshot of the global therapeutic landscape for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1)

• The report reviews Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

• The report reviews key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics and enlists all their major and minor projects

• The report assesses Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

• The report summarizes all the dormant and discontinued pipeline projects

• The report reviews latest news and deals related to Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics

Reasons to buy:

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

• Identify and understand the targeted therapy areas and indications for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1)

• Identify the use of drugs for target identification and drug repurposing

• Identify potential new clients or partners in the target demographic

• Develop strategic initiatives by understanding the focus areas of leading companies

• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

• Devise corrective measures for pipeline projects by understanding Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) development landscape

• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Overview
  • Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • ConSynance Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Drug Profiles
  • AZ-13483342 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • AZD-3857 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • BI-186908 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • CSTI-100 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Small Molecule to Antagonize MCHR1 for Obesity - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Dormant Products
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Discontinued Products
• Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Product Development Milestones
  • Featured News & Press Releases
    • Apr 25, 2018: ConSynance Presents NASH Results
    • Oct 03, 2011: AMRI Presents Final Phase I Clinical Studies Results Of Obesity Compound At 29th Annual Scientific Meeting Of Obesity Society
    • May 31, 2011: AMRI Announces Successful Completion Of Phase I Clinical Study Of Obesity Compound
    • May 19, 2011: AMRI To Present Phase I Clinical Results Of Obesity Compound At European Congress On Obesity
    • Jul 21, 2010: AMRI Initiates Phase I Study Of ALB-127158(a) For Treatment Of Obesity
    • Jun 02, 2009: AMRI Advances New Obesity Drug MCH-1 Receptor Antagonist Toward IND Submission
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
• Disclaimer

List of Tables

• Number of Products under Development by Stage of Development, H2 2018
• Number of Products under Development by Therapy Areas, H2 2018
• Number of Products under Development by Indication, H2 2018
• Number of Products under Development by Companies, H2 2018
• Products under Development by Companies, H2 2018
• Number of Products by Stage and Mechanism of Actions, H2 2018
• Number of Products by Stage and Route of Administration, H2 2018
• Number of Products by Stage and Molecule Type, H2 2018
• Pipeline by AstraZeneca Plc, H2 2018
• Pipeline by Boehringer Ingelheim GmbH, H2 2018
• Pipeline by ConSynance Therapeutics Inc, H2 2018
• Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
• Dormant Projects, H2 2018
• Discontinued Products, H2 2018

List of Figures

• Number of Products under Development by Stage of Development, H2 2018
• Number of Products under Development by Therapy Areas, H2 2018
• Number of Products under Development by Top 10 Indications, H2 2018
• Number of Products by Stage and Mechanism of Actions, H2 2018
• Number of Products by Stage and Route of Administration, H2 2018
• Number of Products by Stage and Molecule Type, H2 2018